Friedrich Sertürner isolated the alkaline substance from opium in 1804, published in 1805, and named it morphium after Morpheus, Ovid's god of dreams, son of Sleep; Merck commercialized it in 1827, and the Civil War's syringes created the first addicted generation, soldier's disease. Felix Hoffmann's 1897 acetylation of morphine produced diacetylmorphine, which Bayer registered as Heroin in 1898, from heroisch, heroic, the testers' word for how it made them feel, marketed as a non-addictive morphine substitute and cough suppressant, sold over the counter, including in children's syrups, until the Harrison Act of 1914.
Ovid's Morpheus shapes dreams, and the morphine literature is one long argument about who owns them: the wounded soldier's relief, the poet's visions, De Quincey's Confessions, the jazzman's horn, Burroughs's algebra of need. Each generation renamed the same transaction, dreams now, payment later, and each pharmaceutical generation promised to separate the dream from the invoice, morphine from opium, heroin from morphine, oxycodone from heroin, the promise itself the product's most reliable side effect.
The claim: the names indict the products, Morpheus admitting the drug rules dreams, heroin admitting it sells borrowed courage, the pharmaceutical industry naming its compounds with an honesty its marketing never matched, the trademark as the one document that never lied. Verdict: the etymologies are documented, the pattern stands, and the archive extends it: every scheduled substance in the modern ledger carries a name that confesses its mechanism, ecstasy, angel dust, speed, the street keeping the industry's own naming tradition. The god of dreams and the hero's courage were always the same molecule in better packaging. The packaging is the part with the patent.
If the drug was named for a god and the upgrade for a hero, what do we call the next refinement?